These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34985607)

  • 21. Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil.
    Pedrana L; Magno L; Zucchi EM; da Silva LAV; Ferraz D; Grangeiro A; Castellanos M; Brasil SA; Dourado I
    BMC Public Health; 2022 Sep; 22(1):1728. PubMed ID: 36096758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA
    Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examining the Awareness, Acceptability, and Adoption of Conventional and non-conventional Forms of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among jail-involved Black Sexual Minority men (BSMM) and Black Transgender Women (BTW) in Two Diverse US Cities.
    Jones MD; Jones K; Almirol E; Payne G; Graves B; Schneider JA; Rijos D; Zawitz C; Zimmerman R; Seal DW; Brewer R; DrPH RB
    AIDS Behav; 2023 Apr; 27(4):1304-1313. PubMed ID: 36264406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women's Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States.
    Philbin MM; Parish C; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
    AIDS Behav; 2021 Mar; 25(3):667-678. PubMed ID: 32910351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferences for Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men Who Have Sex with Men.
    Biello KB; Hosek S; Drucker MT; Belzer M; Mimiaga MJ; Marrow E; Coffey-Esquivel J; Brothers J; Mayer KH
    Arch Sex Behav; 2018 Oct; 47(7):2101-2107. PubMed ID: 28929260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Avoiding Shots in the Dark: Learning from the Past To Inform the Implementation of Long-Acting Injectable Pre-Exposure Prophylaxis for Black American Cisgender Women.
    Irie WC; Mayer K
    AIDS Behav; 2024 Jul; 28(7):2175-2182. PubMed ID: 38605250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model.
    Maloney KM; Le Guillou A; Driggers RA; Sarkar S; Anderson EJ; Malik AA; Jenness SM
    J Infect Dis; 2021 Jan; 223(1):72-82. PubMed ID: 32882043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EquiPrEP: An implementation science protocol for promoting equitable access and uptake of long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP).
    Kaul CM; Moore BE; Kaplan-Lewis E; Casey E; Pitts RA; Pagan Pirallo P; Lim S; Kapadia F; Cohen GM; Khan M; Mgbako O
    PLoS One; 2023; 18(9):e0291657. PubMed ID: 37725628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PrEP for people who use opioids: A NIDA clinical trials network survey study in Southern U.S. cities where HIV incidence is high.
    Hatch MA; Laschober TC; Paschen-Wolff M; Ertl MM; Nelson CM; Wright L; Lancaster C; Feaster DJ; Forrest D; Hankey C; Monger M; Fegley JP; Irving R; Young C; Rose J; Spector A; Dresser L; Moran L; Jelstrom E; Tross S
    Drug Alcohol Depend; 2024 Apr; 257():111133. PubMed ID: 38447393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-acting Injectable PrEP Interest and General PrEP Awareness among People who Inject Drugs in the San Diego-Tijuana Border Metroplex.
    Eger WH; Bazzi AR; Valasek CJ; Vera CF; Harvey-Vera A; Artamonova I; Rangel MG; Strathdee SA; Pines HA
    AIDS Behav; 2024 May; 28(5):1650-1661. PubMed ID: 38319461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men.
    Greene GJ; Swann G; Fought AJ; Carballo-Diéguez A; Hope TJ; Kiser PF; Mustanski B; D'Aquila RT
    AIDS Behav; 2017 May; 21(5):1336-1349. PubMed ID: 27770215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
    Philbin MM; Parish C; Bergen S; Kerrigan D; Kinnard EN; Reed SE; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Alcaide ML; Metsch LR
    AIDS Patient Care STDS; 2021 Jan; 35(1):23-30. PubMed ID: 33400587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferences for long-acting pre-exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey.
    Hsu JH; Ku SW; Chen TW; Li CW; Huang P; Wu HJ; Bourne A; Strong C
    J Int AIDS Soc; 2023 Sep; 26(9):e26163. PubMed ID: 37675767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Associations of HIV Pre-Exposure Prophylaxis Interest and Sexual Risk Behaviors Among Young Black Women.
    Craddock JB; Mangum LC; Aidoo-Frimpong G; Whitfield DL
    AIDS Patient Care STDS; 2021 Jul; 35(7):263-270. PubMed ID: 34242088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Note on Preexposure Prophylaxis Preferences Among Women Who Inject Drugs.
    Miley KL; Tran NK; Elopre L; Groves A; Stockman JK; Bazzi AR; Carrico A; Mazzella S; Roth AM
    Sex Transm Dis; 2023 Oct; 50(10):671-674. PubMed ID: 36728264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis.
    Beckham SW; Sanchez T; Fowler R; Zlotorzynska M; Rai M; Sullivan P; Vannappagari V; Sarkar S; Glick JL; Rinehart AR; Rawlings K; Bridges JFP
    AIDS Patient Care STDS; 2023 Oct; 37(10):495-503. PubMed ID: 37862078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferences for Current and Future PrEP Modalities Among PrEP-Experienced Gay and Bisexual Men in Australia.
    Chan C; Vaccher S; Fraser D; Grulich AE; Holt M; Zablotska-Manos I; Prestage GP; Bavinton BR
    AIDS Behav; 2022 Jan; 26(1):88-95. PubMed ID: 34142274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most.
    Philbin MM; Bergen S; Parish C; Kerrigan D; Kinnard EN; Reed S; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Vaughn M; Gutierrez JI; Fischl MA; Alcaide M; Metsch LR
    AIDS Behav; 2022 Apr; 26(4):1260-1269. PubMed ID: 34648131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.
    Raccagni AR; Galli L; Lucente MF; Candela C; Lolatto R; Trentacapilli B; Ponta G; Messina E; Gianotti N; Castagna A; Nozza S
    AIDS Behav; 2024 Mar; 28(3):907-911. PubMed ID: 37792228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PrEParing for long-acting injectable PrEP in the South: perspectives from healthcare providers in Georgia.
    Xavier Hall CD; Smith JC; Driggers RA; Stoller B; Khan Z; Li J; Ignatius EH; Siegler AJ
    AIDS Care; 2021 Jun; 33(6):706-711. PubMed ID: 32838546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.